Synapse

← Elliott M. Antman

Papers by Elliott M. Antman

Page 2 · newest first

  1. Ideal Cardiovascular Health in Young Adults With Established Cardiovascular DiseasesFrontiers in Cardiovascular Medicine · 2022
  2. Sodium and Health: Old Myths and a Controversy Based on DenialCurrent Nutrition Reports · 2022
  3. Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent PlasmaJAMA Network Open · 2022
  4. Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroupsAmerican Heart Journal · 2022
  5. The inclusion of augmented intelligence in medicine: A framework for successful implementationCell Reports Medicine · 2022
  6. Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48European Heart Journal - Cardiovascular Pharmacotherapy · 2021
  7. Exploring patient experiences coping with using multiple medications: a qualitative interview studyBMJ Open · 2021
  8. A precision medicine approach to sex-based differences in ideal cardiovascular healthScientific Reports · 2021
  9. Ideal Cardiovascular Health in Former SmokersJournal of Clinical Medicine · 2021
  10. Comparative Effectiveness of Aspirin Dosing in Cardiovascular DiseaseNew England Journal of Medicine · 2021
  11. Obesity and Ideal Cardiovascular Health: Results from the My Research Legacy StudyObesities · 2021
  12. Nonprofit Advocacy at the American Heart Association: Creating a Visionary Way Forward at Our 40th Anniversary: An American Heart Association Policy StatementCirculation · 2021
  13. Data from Digital Health Devices Informs Ideal Cardiovascular HealthJournal of Personalized Medicine · 2021
  14. Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial FibrillationJournal of the American College of Cardiology · 2021
  15. Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trialEuropean Heart Journal · 2021
  16. The path to universalityEuropean Journal of Heart Failure · 2021
  17. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 TrialCirculation · 2021
  18. Sex, Permanent Drug Discontinuation, and Study Retention in Clinical TrialsCirculation · 2021
  19. Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 studyAmerican Heart Journal · 2021
  20. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic DiseaseCirculation · 2020
  21. Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF–TIMI 48 TrialCirculation Cardiovascular Quality and Outcomes · 2020
  22. A Biomarker-Centric Approach to Drug Discovery and Development: Lessons Learned from the Coronavirus Disease 2019 PandemicJournal of Pharmacology and Experimental Therapeutics · 2020
  23. Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58 634 patients across four randomized controlled trialsEuropean Heart Journal - Cardiovascular Pharmacotherapy · 2020
  24. Comprehensive characterization of protein-protein interaction network perturbations by human disease mutations2020
  25. Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 TrialThrombosis and Haemostasis · 2020
  26. Pooling Data From Individual Clinical Trials in the COVID-19 EraJAMA · 2020
  27. Managing Stable Ischemic Heart DiseaseNew England Journal of Medicine · 2020
  28. Left Atrial Structure and Function and the Risk of Death or Heart Failure in Atrial FibrillationEuropean Journal of Heart Failure · 2019
  29. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trialEuropean Heart Journal - Cardiovascular Pharmacotherapy · 2019
  30. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 TrialCirculation · 2019
  31. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction).2019
  32. Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 TrialHypertension · 2019
  33. Individual Patient-Level Data Sharing for Continuous Learning: A Strategy for Trial Data SharingNAM Perspectives · 2019
  34. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48Circulation · 2019
  35. Improving Care of STEMI in the United States 2008 to 2012Journal of the American Heart Association · 2018
  36. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trialEuropean Heart Journal · 2018
  37. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trialEuropean Heart Journal · 2018
  38. Fourth universal definition of myocardial infarction (2018)Kardiologia Polska · 2018
  39. The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trialsEuropean Heart Journal Acute Cardiovascular Care · 2018
  40. Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trialsEuropean Heart Journal · 2018
  41. Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 TrialSHILAP Revista de lepidopterología · 2018
  42. Improving care at the population and individual level: lessons from SWEDEHEARTEuropean Heart Journal · 2018
  43. Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF–TIMI 48European Heart Journal Acute Cardiovascular Care · 2018
  44. Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 TrialCirculation · 2018
  45. Gastrointestinal Bleeding With Edoxaban Versus WarfarinCirculation Cardiovascular Quality and Outcomes · 2018
  46. American Heart Association Principles on the Accessibility and Affordability of Drugs and BiologicsCirculation · 2017
  47. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSEuropean Heart Journal · 2017
  48. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSEuropean Journal of Cardio-Thoracic Surgery · 2017
  49. Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 TrialJournal of the American Heart Association · 2017
  50. Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF‐TIMI 48 TrialJournal of the American Heart Association · 2017